These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 19221315

  • 1. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
    Rascol O.
    Neurology; 2009 Feb 17; 72(7 Suppl):S51-8. PubMed ID: 19221315
    [Abstract] [Full Text] [Related]

  • 2. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke CE.
    Mov Disord; 2008 Apr 30; 23(6):784-9. PubMed ID: 18175348
    [Abstract] [Full Text] [Related]

  • 3. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE.
    Mov Disord; 2004 May 30; 19(5):491-8. PubMed ID: 15133811
    [Abstract] [Full Text] [Related]

  • 4. Neuroprotection in Parkinson's disease: clinical trials.
    Stocchi F, Olanow CW.
    Ann Neurol; 2003 May 30; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
    [Abstract] [Full Text] [Related]

  • 5. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ, Swope DM, Dashtipour K.
    Clin Ther; 2007 Sep 30; 29(9):1825-49. PubMed ID: 18035186
    [Abstract] [Full Text] [Related]

  • 6. When and how should treatment be started in Parkinson disease?
    Lang AE.
    Neurology; 2009 Feb 17; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [Abstract] [Full Text] [Related]

  • 7. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, Palm R, Swedish Parkinson Study Group.
    Neurology; 2006 Apr 25; 66(8):1200-6. PubMed ID: 16540603
    [Abstract] [Full Text] [Related]

  • 8. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort InvestigatorsDepartment of Neurology, University of Rochester, 1351 Mt Hope Ave, Ste 220, Rochester, NY 14620, USA. kevin.biglan@ctcc.rochester.edu.
    Arch Neurol; 2009 May 25; 66(5):563-70. PubMed ID: 19433655
    [Abstract] [Full Text] [Related]

  • 9. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ.
    Clin Ther; 2009 Jan 25; 31(1):89-98. PubMed ID: 19243709
    [Abstract] [Full Text] [Related]

  • 10. Minimal clinically important change on the unified Parkinson's disease rating scale.
    Schrag A, Sampaio C, Counsell N, Poewe W.
    Mov Disord; 2006 Aug 25; 21(8):1200-7. PubMed ID: 16673410
    [Abstract] [Full Text] [Related]

  • 11. [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].
    Linazasoro G, Sesar A, Valldeoriola F, Compta Y, Herrero MT, Martínez Castrillo JC, López Lozano JJ, Bergaretxe A, Vela L, Fernández JM, Castro A, Kulisevski J, Lezcano E, Vaamonde J, López Del Val J, Chacón J, Vivancos F, Luquin R, Aguilar M, Burguera JA, Salvador C, Menéndez Guisasola L, Catalán MJ, Mir P, Campos V, Grandas F, Mínguez A, Balaguer E, Yáñez R, Leiva C, García Ruiz P, Cubo E.
    Neurologia; 2009 Mar 25; 24(2):113-24. PubMed ID: 19322690
    [Abstract] [Full Text] [Related]

  • 12. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.
    Schapira AH.
    Neurology; 2009 Feb 17; 72(7 Suppl):S44-50. PubMed ID: 19221314
    [Abstract] [Full Text] [Related]

  • 13. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW.
    Neurology; 2009 Feb 17; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [Abstract] [Full Text] [Related]

  • 14. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.
    Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, Shannon K, Wooten GF, Tanner CM, Goetz GC, NET-PD Investigators.
    Neurology; 2006 Mar 14; 66(5):628-33. PubMed ID: 16534099
    [Abstract] [Full Text] [Related]

  • 15. Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings.
    Marras C, Lang AE.
    Expert Rev Neurother; 2004 Nov 14; 4(6):985-93. PubMed ID: 15853525
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.